Sparx | Jotup

Sparx Hockey Acquires 20th International Patent Reinforcing Its Technology Leadership Position In Skate Sharpening

Retrieved on:

Friday, March 22, 2024

Apple, IPhone, Research, History, Blackberry, Hockey, Sparx, Invention, Patent, USD, Paper, Engraving

ACTON, Mass., March 22, 2024 /PRNewswire/ -- Sparx Hockey, inventors of the innovative Sparx Skate Sharpener, today announced it has secured its 20th global patent, securing the company's position as the No. 1 brand in skate sharpening and the undisputed leader in automated sharpening technology.

Key Points:

1 Brand in Skate Sharpening With Innovative Alignment Patent That Allows The Sparx Sharpener To Achieve Unmatched Accuracy
ACTON, Mass., March 22, 2024 /PRNewswire/ -- Sparx Hockey, inventors of the innovative Sparx Skate Sharpener, today announced it has secured its 20th global patent, securing the company's position as the No.
The company's patented, innovative alignment system is combined with the latest in laser alignment technology in Sparx Hockey's flagship product, the Sparx Sharpener 3.
More than 8 million sharpenings per year are conducted using Sparx Sharpening technology, making Sparx Hockey the No.
For more information about Sparx Hockey or to purchase the new Sparx Sharpener 3 or Sparx Sharpener 3 Pro, visit www.sparxhockey.com

Kite and Arcellx Announce Expansion in Strategic Partnership

Retrieved on:

Wednesday, November 15, 2023

“Given this, we are deepening our relationship with Arcellx to further support advancement of CART-ddBCMA, bolster our pipeline in multiple myeloma, as well as access opportunities in lymphoma.

Key Points:

“Given this, we are deepening our relationship with Arcellx to further support advancement of CART-ddBCMA, bolster our pipeline in multiple myeloma, as well as access opportunities in lymphoma.
In expanding our strategic partnership with Arcellx, we are building upon the established synergy between Arcellx’s platform technologies and Kite’s industry-leading position in CAR T manufacturing and commercialization."
“Since entering into this strategic collaboration with Kite almost one year ago, we are thrilled with how the partnership is rapidly progressing and the alignment across our teams,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer.
Importantly, these efficiencies embody the trust developed with our Kite partners and do not alter the original agreement in principle or economics.

SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2/PD-L1 Antibody Drug

Retrieved on:

Monday, October 30, 2023

FDA, PD-L1, Trial of the century, Sparx, IND, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biopharmaceutical, LILRB2, Neoplasm, Immune system, Cancer, Safety, Patient, Pharmaceutical industry, Vaccine

CHICAGO, Oct. 30, 2023 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA).

Key Points:

CHICAGO, Oct. 30, 2023 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA).
This approval propels SparX's enduring commitment to deliver groundbreaking solutions to patients grappling with advanced or refractory solid tumors.
Dr. Gui-Dong Zhu, Chief Executive Officer of SparX Biopharmaceutical, shared his exhilaration: "Receiving the FDA's green light on our IND application is a seminal moment in our ongoing journey to redefine the paradigms of cancer treatment.
Developed by SparX, SPX-303 is a First-in-Its Class bispecific antibody therapy, ingeniously engineered to engage two cardinal immune checkpoint proteins, LILRB2 and PD-L1, simultaneously.

The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy

Retrieved on:

Tuesday, October 10, 2023

Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.

Key Points:

Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.
Invariant Natural Killer T (iNKT) cells, distinguished by their recognition of lipid antigens via the CD1d molecule, have emerged as potent therapeutic vectors.
We profoundly acknowledge CLDN 18.2-iNKT cell therapy as a groundbreaking paradigm in oncological therapeutics."
The pathological architecture of tumor development often exposes the CLDN18.2, rendering it accessible to novel treatments such as CAR-iNKT cell therapies.

Sparx Biopharmaceutical Welcomes Dr. Roland Meier as Chief Medical Officer

Retrieved on:

Tuesday, September 5, 2023

University of Zurich, University, University of California, Berkeley, Blas, Biotechnology, Sparx, Eli Lilly, Kyowa Kirin, UC, Patent, Cancer, Knowledge, ADC, University of Lausanne, Fine chemical, Pharmaceutical industry

CHICAGO, Sept. 5, 2023 /PRNewswire/ -- Spearheading the field of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces the addition of Dr. Roland Meier as their esteemed Chief Medical Officer.

Key Points:

CHICAGO, Sept. 5, 2023 /PRNewswire/ -- Spearheading the field of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces the addition of Dr. Roland Meier as their esteemed Chief Medical Officer.
Dr. Guidong Zhu, CEO and founder of SparX, commented, "Dr. Meier's esteemed reputation in immuno-oncology drug development is unparalleled.
With Roland on board, we are poised to transition SparX from a discovery-centric to a clinical-driven biotech entity."
On becoming a part of the SparX family, Dr. Meier shared, "SparX exemplifies innovation in biotechnology.

Sparx Engineering Expands with New Dallas-Area Office

Retrieved on:

Wednesday, May 10, 2023

Regulation and licensure in engineering, Growth, Braniff Building, Biomedical technology, Engineering, Automation, Construction, Industrial design, Sparx, Metroplex

DALLAS, May 10, 2023 /PRNewswire/ -- Sparx Engineering, which was established in Houston in 2009 by co-founders David Headley, Rick Pettys, and Paul Hoopingarner, has announced the opening of a new office in Dallas. The office will be located in the historic Braniff Building and will provide clients with short- or long-term access to a cross-functional team of engineers with decades of experience.

Key Points:

DALLAS, May 10, 2023 /PRNewswire/ -- Sparx Engineering, which was established in Houston in 2009 by co-founders David Headley, Rick Pettys, and Paul Hoopingarner, has announced the opening of a new office in Dallas.
"We're excited to be expanding our presence into the Dallas area" said Paul Hoopingarner, co-founder of Sparx Engineering.
"The scale of Sparx's engineering team, expertise, and resources is typically only found in companies with over a thousand employees."
Said Rick Pettys, co-founder of Sparx Engineering.

SPARX TECHNOLOGY INC. ENGAGES CAMERON THOMSON GROUP

Retrieved on:

Tuesday, January 17, 2023

CTG, History, Sparx

VANCOUVER, BC, Jan. 17, 2023 /PRNewswire/ - Sparx Technology Inc. (TSXV: SPRX) (OTCQB: STCXF) ("Sparx" or the "Company") is excited to announce that Sparx has engaged Cameron Thomson Group Ltd. ("CTG") to strengthen their sales force and expand their footprint in North America, Europe and Asia.

Key Points:

VANCOUVER, BC, Jan. 17, 2023 /PRNewswire/ - Sparx Technology Inc. (TSXV: SPRX) (OTCQB: STCXF) ("Sparx" or the "Company") is excited to announce that Sparx has engaged Cameron Thomson Group Ltd. ("CTG") to strengthen their sales force and expand their footprint in North America, Europe and Asia.
Cameron Thomson Group Ltd. is a business development company specializing in providing corporate development, financing and business evolution services to the media/entertainment and technology industries.
Cameron Thomson Group is based in Toronto, Canada, with offices in London, Lake Como-Italy, Los Angeles, and Taipei.
Al Thorgeirson, CEO and President, commented, "The Cameron Thomson Group brings a wide array of experience and a history of success in multiple areas.

SPARX ANNOUNCES 2022 YEAR-END FINANCIAL RESULTS

Retrieved on:

Friday, October 28, 2022

The increase in revenue in 2022, is primarily attributable to the addition of a Canadian Chartered Bank customer who utilized the Company's Sparx Studio platform during the second quarter of the 2022 fiscal year.

Key Points:

The increase in revenue in 2022, is primarily attributable to the addition of a Canadian Chartered Bank customer who utilized the Company's Sparx Studio platform during the second quarter of the 2022 fiscal year.
In total, the Company added six new enterprise customers to their portfolio during the 2022 fiscal year.
Operating expenses saw an increase due to professional and consulting fees relating to the reverse takeover in Q3 of 2022.
Further increases in the fiscal year 2022 are a result of the non-cash listing fee expense and stock-based compensation awarded to Sparx employees, consultants and directors, as part of the reverse takeover, which occurred between March 23, 2022 to June 30, 2022.

NESN TO USE SPARX PLATFORM FOR 2022-2023 BOSTON BRUINS BROADCASTS

Retrieved on:

Tuesday, October 25, 2022

News, Funding, TSX, Boston Bruins, Transaction, NESN, COVID-19, Multimedia, Company, New England Sports Network, TSX Venture Exchange, Nature, Forward-looking statement, Boston, View, Public relations, Online shopping, Sparx, BC

VANCOUVER, BC, Oct. 25, 2022 /PRNewswire/ - Sparx Technology Inc. (TSXV: SPRX) (OTCQB: STCXF) ("Sparx" or the "Company")is excited to announce that Sparx and New England Sports Network ("NESN") have agreed to extend their current statement of work for the length of the Boston Bruins regular season where NESN will have unlimited use of the Company's real-time platform in their broadcasts of live Boston Bruins games.

Key Points:

VANCOUVER, BC, Oct. 25, 2022 /PRNewswire/ - Sparx Technology Inc. (TSXV: SPRX) (OTCQB: STCXF) ("Sparx" or the "Company")is excited to announce that Sparx and New England Sports Network ("NESN") have agreed to extend their current statement of work for the length of the Boston Bruins regular season where NESN will have unlimited use of the Company's real-time platform in their broadcasts of live Boston Bruins games.
The Sparx real-time platform is flexible, multi-faceted and is used to engage audiences with voting/polling, predictive questions and trivia.
Sparx is an interactive media technology company whose principal activities are providing media companies and sports teams with technologies to engage audiences.
Millions of users can connect to the Sparx platform and interact simultaneously on their mobile phone, tablet, or computer anywhere in the world, in real time.

PORTLAND TRAIL BLAZERS TO USE SPARX PLATFORM FOR 2022-2023 SEASON

Retrieved on:

Monday, October 24, 2022

VANCOUVER, BC, Oct. 24, 2022 /PRNewswire/ - Sparx Technology Inc. (TSXV: SPRX) (OTCQB: STCXF) ("Sparx" or the "Company")is excited to announce that the Portland Trail Blazers have engaged Sparx for the licensing of the Company's real-time platform for the 2022-2023 NBA season.

Key Points:

VANCOUVER, BC, Oct. 24, 2022 /PRNewswire/ - Sparx Technology Inc. (TSXV: SPRX) (OTCQB: STCXF) ("Sparx" or the "Company")is excited to announce that the Portland Trail Blazers have engaged Sparx for the licensing of the Company's real-time platform for the 2022-2023 NBA season.
The Sparx real-time platform is flexible, multi-faceted and is used to engage audiences with voting/polling, predictive questions and trivia.
On the engagement with Portland Trail Blazers, Al Thorgeirson, CEO and President, commented the following, "We are excited to bring the Portland Trail Blazers into our growing NBA clientele.
Kevin Kinghorn, Chief Marketing Officer and Executive Vice President, at the Portland Trail Blazers added, "The Portland Trail Blazers are focused on innovation in the broadcast space with the sole intent of creating a more entertaining, engaging, and interactive broadcast for our fans.